The Effect of Resistance Training and Aerobic Training on Body Composition During Chemotherapy

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02192216
• Date of registration: 04/07/2014
• Prospective Registration: No
• Primary sponsor: Department of Public Health, Denmark
• Public title: The Effect of Resistance Training and Aerobic Training on Body Composition During Chemotherapy
• Scientific title: The Effect of Resistance Training and Aerobic Training on Body Composition During Chemotherapy
• Date of first enrolment: February 2014
• Target sample size: 16
• Recruitment status: Terminated
• URL: https://clinicaltrials.gov/show/NCT02192216
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).
• Phase: N/A

Countries of recruitment

Denmark

Contacts

• Name: Simon Loenbro, M.Sc., PhD
• Affiliation: Dept. of Public Health, Sect. for Sports Science, Aarhus University

Key inclusion & exclusion criteria

Inclusion Criteria:

- Currently receiving curative, adjuvant, neo-adjuvant or palliative chemotherapy

- No documented bone metastases or myelomatosis

- No documented CNS affection

- WHO performance status 0-1

- No chronical thrombocytopenia or leukopenia

- No physical conditions preventing exercise participation

- No serious symptoms of heart disease

- No dementia or mental illness preventing participation

- Signed written concent

- Age above 18 years

Exclusion Criteria:

- Participation in systematic resistance training three months prior to inclusion



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Neoplasms

Intervention(s)

Behavioral: Exercise

Primary Outcome(s)

Changes in body composition [Time Frame: Assessment before (baseline) and after (pre-training) the control period of 7 weeks (average), where patients recieve chemotherapy, and again after completion of 10 weeks of exericse (post-training).]

Secondary Outcome(s)

Changes in cancer related fatigue and quality of life [Time Frame: Assessment before (baseline) and after (pre-training) the control period of 7 weeks (average), where patients recieve chemotherapy, and again after completion of 10 weeks of exericse (post-training).]

Changes in aerobic performance [Time Frame: Assessment before (baseline) and after (pre-training) the control period of 7 weeks (average), where patients recieve chemotherapy, and again after completion of 10 weeks of exericse (post-training).]

Changes in functional performance [Time Frame: Assessment before (baseline) and after (pre-training) the control period of 7 weeks (average), where patients recieve chemotherapy, and again after completion of 10 weeks of exericse (post-training).]

Changes in dynamic muscle strength [Time Frame: Assessment before (baseline) and after (pre-training) the control period of 7 weeks (average), where patients recieve chemotherapy, and again after completion of 10 weeks of exericse (post-training).]

Changes in underlying biological mechanisms associated with changes in muscle mass [Time Frame: Assessment before (baseline) and after (pre-training) the control period of 7 weeks (average), where patients recieve chemotherapy, and again after completion of 10 weeks of exericse (post-training).]

Secondary ID(s)

41408

SKDM2014

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Aarhus University Hospital